Free tool
FAERS Monitor: Ingrezza Sprinkle
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218390 or its brand name (Ingrezza Sprinkle, Valbenazine Tosylate). Reports on generic versions are filed under their own applications.
Reports
426
Serious
367
86% of reports
Hospitalization
142
Death reported
56
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- tardive dyskinesia90
- off label use31
- somnolence31
- completed suicide20
- depression19
- parkinsonism16
- dyskinesia15
- fall15
- suicidal ideation14
- anxiety13
- malaise13
- drug ineffective12
- dysphagia12
- hospitalisation12
- tremor11
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 2 |
| 2018 | 8 |
| 2019 | 8 |
| 2020 | 21 |
| 2021 | 18 |
| 2022 | 74 |
| 2023 | 103 |
| 2024 | 100 |
| 2025 | 55 |
| 2026 | 37 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,733 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| tardive dyskinesiaSignal | 90 | 158.0 | 131.5 | 13,859 |
| parkinsonismSignal | 16 | 81.2 | 50.2 | 1,186 |
| dyskinesiaSignal | 15 | 18.2 | 11.1 | 228 |
| completed suicideSignal | 20 | 11.9 | 7.7 | 189 |
| somnolenceSignal | 31 | 7.6 | 5.4 | 173 |
| suicidal ideationSignal | 14 | 7.6 | 4.5 | 73 |
| dysphagiaSignal | 12 | 6.2 | 3.6 | 48 |
| depressionSignal | 19 | 4.1 | 2.7 | 42 |
| hospitalisationSignal | 12 | 3.9 | 2.2 | 23 |
| tremorSignal | 11 | 3.3 | 1.8 | 15 |
| anxietySignal | 13 | 2.3 | 1.3 | 8 |
| fallSignal | 15 | 2.2 | 1.4 | 9 |
| off label use | 31 | 1.7 | 1.2 | 10 |
| malaise | 13 | 1.5 | 0.9 | 2 |
| drug ineffective | 12 | 0.4 | 0.3 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.